RITA KAMMIEL: Open Payments
NPI 1427142736 · ABSECON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,602 in 97 payments from 15 companies in 2025. Trend: 2023 $2,510 · 2024 $2,006 · 2025 $1,602
Food & beverage: $1,602
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $270 |
| ABBVIE INC. | 13 | $226 |
| Neurocrine BioSciences, Inc. | 11 | $163 |
| Axsome Therapeutics, Inc. | 9 | $162 |
| Lundbeck LLC | 9 | $139 |
| Otsuka America Pharmaceutical, Inc. | 8 | $137 |
| E.R. Squibb & Sons, L.L.C. | 7 | $115 |
| Bausch Health US, LLC | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
Products named: REXULTI, VRAYLAR, ARISTADA, INGREZZA, Auvelity, COBENFY, APLENZIN, FANAPT.
Industry payments across NJ — which companies pay providers there.
